ZUBSOLV® is indicated for the maintenance treatment of opioid use disorder (OUD) and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. The drug is based on Orexo´s sublingual drug delivery platform and is available in six dosage strengths.
Pharmaceuticals
ZUBSOLV®
(buprenorphine and naloxone) Sublingual tablet (CIII)
Orexo commercializes ZUBSOLV® in the US. In the EU, ZUBSOLV® is commercialized by Orexo´s partner Accord Healthcare. Rights to other markets are owned by Orexo.
Abstral®
Abstral® is indicated for treatment of breakthrough cancer pain, developed based on the company´s sublingual drug delivery platform.
Kyowa Kirin provides commercialization of Abstral® outside the US and EU, where patents have expired.
Edluar®
Edluar® is indicated for the treatment of short-term insomnia, developed based on the company´s sublingual drug delivery platform.
Viatris provides commercialization of Edluar® worldwide outside the US.
Digital Mental Health Programs
MODIA®
for OUD
MODIA® is a 6-month digital mental health program designed to help patients with OUD develop behavioral coping skills. MODIA® incorporates various supportive techniques like cognitive behavioral therapy (CBT) and motivational interviewing. MODIA® is intended for use by patients who are engaged in a clinician directed Medication-Assisted Treatment (MAT) plan for OUD.1,2
Developed in collaboration with GAIA AG
vorvida®
for alcohol management
Vorvida® is a 6-month digital mental health program to help individuals reduce their alcohol use and help them manage their drinking behavior. Vorvida® uses CBT-based tools and techniques to help patients identify triggers, break negative behaviors, and develop healthier responses to alcohol. The effectiveness of vorvida® is evaluated in randomized clinical trial, including approximately 600 patients.3,4,5
Developed by GAIA AG
deprexis®
for depression
Deprexis® is a 3-month digital mental health program that can help people create more positive thoughts and behaviors using trusted CBT-based techniques. Its effectiveness has been evaluated and published in 12 randomized clinical trials (RCTs) including more than 2,800 patients. Deprexis® can be added to any treatment plan.6,7,8,9
Developed by GAIA AG
References: 1. MODIA® Instructions for Use. Oct 2023. 2. Meyer B, et al. JMIR Ment Health. 2021;8(10):e31173. 3. vorvida® Instructions for Use. Jan 2023. 4. Zill J, et al. Dtsch Arztebl Int. 2019;116(8):127-133. 5. Carroll KM, Psychol Addict Behav. 2017;31(8)847-861. 6. deprexis Instructions for Use. Apr 2023. 7. APA Div. 12. What is Cognitive Behavioral Therapy? March 2021. 8. Meyer B. et al. Internet Interv. 2015;2(1):48-59 9. Twomey C, et al. PLoS One. 2020;15(1):e0228100.